Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers

Life Sciences

Volumn 85, Issue 7-8, 2009, Pages 281-290

  Cho, Yong Kyun ^a   Yun, Jung Won ^a   Park, Jung Ho ^a   Kim, Hong Joo ^a   Park, Dong Il ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a   Jin, Wook ^b   Kwon, Yong Hyun ^c   Shin, Mi Kyung ^c   Yoo, Tae Moo ^d   Kang, Ju Hee ^c   Park, Chang Shin ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Korea Food and Drug Administration   (South Korea)

Author keywords

Carbon tetrachloride; Caveolin 1; Endothelial nitric oxide synthase; Liver cirrhosis; Silymarin

Indexed keywords

ADENYLATE KINASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CAVEOLIN 1; COLLAGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIVER ENZYME; NITRIC OXIDE; OXYHEMOGLOBIN; PROTEIN KINASE B; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEMODYNAMICS; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARBON TETRACHLORIDE; COLLAGEN; GENE EXPRESSION; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TESTS; MALE; NITRIC OXIDE SYNTHASE TYPE III; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SILYMARIN;

RATTUS;

EID: 67749113148     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.06.001     Document Type: Article

References (56)

1. Abdalla M.Y., Britigan B.E., Wen F., Icardi M., McCormick M.L., LaBrecque D.R., Voigt M., Brown K.E., and Schmidt W.N. Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. The Journal of Infectious Diseases 190 6 (2004) 1109-1118
2. 4 model of liver fibrosis in rats. Scientific World Journal 7 (2007) 1242-1255
3. 4 cirrhotic rats. Journal of Hepatology 46 6 (2007) 1040-1046
4. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology 1 2 (2002) 72-79
5. Bosch J., and Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. Journal of Hepatology 32 1 (2000) 141-156
6. Butt E., Nernhardt M., Smolenski A., Kotsonis P., Fröhlich L.G., Sickmann A., Meyer H.E., Lohmann S.M., and Schmidt H.H. Endothelial nitric-oxide synthase (Type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. The Journal of Biological Chemistry 275 7 (2000) 5179-5187
7. Chen Z.P., Mitchelhil K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., and Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Letters 443 3 (1999) 285-289
8. Dehmlow C., Erhard J., and de Groot H. Inhibition of Kupffer cell function as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 4 (1996) 749-754
9. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 6736 (1999) 601-605
10. Farghali H., Kamenikova L., Hynie S., and Kmonickova E. Silymarin effects on intracellular calcuim and cytotoxicity: A study in perfused rat hepatocytes after oxidative stress injury. Pharmacological Research 41 2 (2000) 231-237
11. Feelish M., Kubitzek D., and Werringloer J. In: Feelisch M., and Stammler J.S. (Eds). The Oxyhaemoglobin Assay in Methods in Nitric Oxide Research (1996), Wiley, New York 455-478
12. Flores O., Criado M., Sanchez-Rodriguez A., Hidalgo F., Collía F., López-Novoa J.M., and Esteller A. Relationships between NOS2 and HO-1 in liver of rats with chronic bile duct ligation. Hepatology Research 32 1 (2005) 58-65
13. Goh B.J., Tan B.T., Hon W.M., Lee K.H., and Khoo H.E. Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosis. World Journal of Gastroenterology 12 4 (2006) 588-594
14. Gupta T.K., Toruner M., Chung M.K., and Groszmann R.J. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 4 (1998) 926-931
15. Huber R., Jutter I., and Ludtke R. Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. European Journal of Medical Research 10 2 (2005) 68-70
16. Iwakiri Y. The molecules: Mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. Journal of Clinical Gastroenterology 41 3 (2007) S288-S294
17. Iwakiri Y., and Groszmann R.J. Vascular endothelial dysfunction in cirrhosis. Journal of Hepatology 46 5 (2007) 927-934
18. Jamall I.S., Finelli V.N., and Que Hee S.S. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Analytical Biochemistry 112 1 (1981) 70-75
19. Jeong D.H., Lee G.P., Jeong W.I., Do S.H., Yang H.J., Yuan D.W., Park H.Y., Kim K.J., and Jeong K.S. Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis. World Journal of Gastroenterology 11 8 (2005) 1141-1148
20. Jiang C., Agarwal R., and Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communication 276 1 (2000) 371-378
21. Jin Y., Kim H.P., Chi M., Ifedigbo E., Ryter S.W., and Choi A.M. Deletion of caveolin-1 protects against oxidative lung injury via up-regulation of heme oxygenase-1. American Journal of Respiratory Cell and Molecular Biology 39 2 (2008) 171-179
22. Johnson V.J., Osuchowski M.F., He Q., and Sharma R.P. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. Alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Medica 68 11 (2002) 961-965
23. Kim H.P., Wang X., Galbiati F., Ryter S.W., and Choi A.M. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. The FASEB Journal 18 10 (2004) 1080-1089
24. Klinge C.M., Wickramasinghe N.S., Ivanova M.M., and Dougherty S.M. Resveratrol stimulates nitric oxide production by increasing estrogen receptor {alpha}-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. The FASEB Journal 22 7 (2008) 2185-2197
25. Laleman W., Landeghem L., Wilmer A., Fevery J., and Nevens F. Portal hypertension: From pathophysiology to clinical practice. Liver International 25 6 (2005) 1079-1090
26. Lee G.P., Jeong W.I., Jeong D.H., Do S.H., Kim T.H., and Jeong K.S. Diagnostic evaluation of carbon tetrachloride-induced rat hepatic cirrhosis model. Anticancer Research 25 2A (2008) 1029-1038
27. Liu S., Premont R.T., Kontos C.D., Zhu S., and Rockey D.C. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nature Medicine 11 9 (2005) 952-958
28. Loureiro-Silva M.R., Cadelina G.W., Iwakiri Y., and Groszmann R.J. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. Journal of Hepatology 39 6 (2003) 940-946
29. Malyshev E., Tazi K.A., Moreau R., and Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. Journal of Gastroenterology and Hepatology 22 12 (2007) 2195-2201
30. 4 cirrhosis. Hepatology 44 1 (2006) 44-52
31. Matsumi M., Takahashi T., Fujii H., Ohashi I., Kaku R., Nakatsuka H., Shimizu H., Morita K., Hirakawa M., Inagaki M., Sadamori H., Yagi T., Tanaka N., and Akagi R. Increased heme oxygenase-1 gene expression in the livers of patients with portal hypertension due to severe hepatic cirrhosis. The Journal of International Medical Research 30 3 (2002) 282-288
32. McCarty M.F., and Block K.I. Multifocal angiostatic therapy: An update. Integrative Cancer Therapies 4 4 (2005) 301-314
33. Morales-ruiz M., Cejudo-Martin P., Fernandez-varo G., Tugues S., Ros J., Angeli P., Rivera F., Arroyo V., Rodés J., Sessa W.C., and Jiménez W. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 125 2 (2003) 522-531
34. 4 administration in the rat after discontinuation of treatment: Effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic and Clinical Pharmacology and Toxicology 96 5 (2005) 375-380
35. Pradhan S.C., and Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. The Indian Journal of Medical Research 124 5 (2006) 491-504
36. Proctor E., and Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 83 6 (1982) 1183-1190
37. Rockey D.C., and Chung J.J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 114 2 (1998) 344-351
38. Ros J., Jimenez W., Lamas S., Clària J., Arroyo V., Rivera F., and Rodés J. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 21 2 (1995) 554-560
39. Saliou C., Rihn B., Cillard J., Okamoto T., and Packer L. Selective inhibition of NF-kB activation by the flavonoid hepatoprotector silymarin in HepG2. FEBS Letters 440 1-2 (1998) 8-12
40. Saller R., Meier R., and Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 61 14 (2001) 2035-2063
41. Saller R., Brignoli R., Melzer J., and Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forschende Komplementarmedizin 15 1 (2008) 9-20
42. Salter M., and Knowles R.G. Assay of NOS activity by the measurement of conversion of oxyhemoglobin to methemoglobin by NO. Methods in Molecular Biology 100 (1998) 61-65
43. Sarela A.I., Mihaimeed F.M., Batten J.J., Davidson B.R., and Mathie R.T. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 44 5 (1999) 749-753
44. Schuppan D., and Afdhal N.H. Liver cirrhosis. Lancet 371 9615 (2008) 838-851
45. Shah V., Toruner M., Haddad F., Cadelina G., Papapetropoulos A., Choo K., Sessa W.C., and Groszmann R.J. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117 5 (1999) 1222-1228
46. Shah V., Cao S., Hendrickson H., Yao J., and Katusic Z.S. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. American Journal of Physiology, Gastrointestinal and Liver Physiology 280 6 (2001) G1209-G1216
47. Soucy K.G., Ryoo S., Benjo A., Lim H.K., Gupta G., Sohi J.S., Elser J., Aon M.A., Nyhan D., Shoukas A.A., and Berkowitz D.E. Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness. Journal of Applied Physiology 101 6 (2006) 1751-1759
48. Suematsu M., Kashiwagi S., Sano T., Goda N., Shinoda Y., and Ishimura Y. Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. Biochemical and Biophysical Research Communications 205 2 (1994) 1333-1337
49. Tsai J.H., Liu J.Y., Wu T.T., Ho P.C., Huang C.Y., Shyu J.C., Hsieh Y.S., Tsai C.C., and Liu Y.C. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. Journal of Viral Hepatitis 15 7 (2008) 508-514
50. Wei C.L., Lee K.H., Khoo H.E., and Hon W.M. Expression of haem oxygenase in cirrhotic rat liver. The Journal of Pathology 199 3 (2003) 324-334
51. Wellington K., and Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 15 7 (2001) 465-489
52. Yang W., Benjamin I.S., Moore K., Portmann B., and Alexander B. The action of nitric oxide on hepatic haemodynamics during secondary biliary cirrhosis in the rat. European Journal of Pharmacology 461 1 (2003) 41-48
53. Yokomori H., Oda M., Ogi M., Sakai K., and Ishii H. Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis. Liver 22 2 (2002) 150-158
54. Yokomori H., Oda M., Yoshimura K., Nomura M., Wakabayashi G., Kitajima M., and Ishii H. Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: Relation with nitric oxide. Journal of Gastroenterology 38 9 (2003) 854-860
55. Yokomori H., Oda M., Wakabayashi G., Kitajima M., Yoshimura K., Nomura M., and Hibi T. High expressions of caveolins on the proliferating bile ductules in primary biliary cirrhosis. World Journal of Gastroenterology 11 24 (2005) 3710-3713
56. Zakhary R., Poss K.D., Jaffrey S.R., Ferris C.D., Tonegawa S., and Snyder S.H. Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. Proceedings of the National Academy of Sciences of the United States of America 94 26 (1997) 14848-14853